Intellia Therapeutics
NTLA
241 hedge funds and large institutions have $3.36B invested in Intellia Therapeutics in 2020 Q4 according to their latest regulatory filings, with 94 funds opening new positions, 68 increasing their positions, 50 reducing their positions, and 17 closing their positions.
453% more first-time investments, than exits
New positions opened: 94 | Existing positions closed: 17
198% more capital invested
Capital invested by funds: $1.13B → $3.36B (+$2.23B)
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
46% more funds holding
Funds holding: 165 → 241 (+76)
36% more repeat investments, than reductions
Existing positions increased: 68 | Existing positions reduced: 50
8.33% more ownership
Funds ownership: 96.17% → 104.5% (+8.3%)
80% less call options, than puts
Call options by funds: $16.9M | Put options by funds: $83.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Invesco
Atlanta,
Georgia
|
+$42.6M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$27.4M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$24.1M |
| 4 |
Goldman Sachs
New York
|
+$18.8M |
| 5 |
MWNA
Marshall Wace North America
New York
|
+$17.4M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAMA
Nikko Asset Management Americas
New York
|
-$34.8M |
| 2 |
Sumitomo Mitsui Trust Group
Minato-Ku, Tokyo,
Japan
|
-$34.8M |
| 3 |
State Street
Boston,
Massachusetts
|
-$29.6M |
| 4 |
BlackRock
New York
|
-$21.5M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$18.4M |
NTLA Hedge Fund Activity: Q4 2020 in Review
241 of the 5,676 institutional investors tracked by Wall St. Rank reported a position in Intellia Therapeutics (NTLA) for Q4 2020, worth a combined $3.36B — up 198% from $1.13B a quarter earlier.
Buyers outnumbered sellers: 94 funds opened new NTLA positions and 17 closed out — a net gain of 77 holders — while 68 added to existing stakes and 50 trimmed.
The largest buyer was Invesco, adding an estimated $42.6M. The largest seller was Nikko Asset Management Americas, cutting an estimated $34.8M.
- 241 institutional investors held Intellia Therapeutics (NTLA) as of Q4 2020, up from 165 in Q3 2020.
- Funds reported $3.36B of Intellia Therapeutics stock for Q4 2020, up 198% quarter-over-quarter.
- 94 funds opened new Intellia Therapeutics positions in Q4 2020 and 17 closed out, a net change of +77 holders.
- The largest Intellia Therapeutics buyer in Q4 2020 was Invesco, an estimated $42.6M added.
- The largest Intellia Therapeutics seller in Q4 2020 was Nikko Asset Management Americas, an estimated $34.8M sold.
Based on aggregated 13F filings for Q4 2020.